PLL Therapeutics opens subsidiary in New Zealand to accelerate ALS (Amyotrophic Lateral Sclerosis) treatment and early diagnostics breakthroughs
Expansion in Asia-Pacific with second subsidiary, following Australia, pivotal to enrolling patients in phase II trial targeting ALS, a motor neuron disease with no cure....











